The Association of methylprednisolone dosing to cessation of
myotonia in a patient with myotonic dystrophy type 1

J 2020

The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1

HORÁKOVÁ, Magda, Tomáš HORÁK, Josef BEDNAŘÍK and Stanislav VOHÁŇKA

Basic information

Original name

The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1

Authors

HORÁKOVÁ, Magda (203 Czech Republic, belonging to the institution), Tomáš HORÁK (203 Czech Republic, guarantor, belonging to the institution), Josef BEDNAŘÍK (203 Czech Republic, belonging to the institution) and Stanislav VOHÁŇKA (203 Czech Republic, belonging to the institution)

Edition

Neuromuscular Disorders, London, Elsevier, 2020, 0960-8966

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30103 Neurosciences

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.296

RIV identification code

RIV/00216224:14110/20:00115973

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.nmd.2020.03.004

UT WoS

000539369800009

Keywords in English

Myotonia; Myotonic dystrophy; Methylprednisolone; Corticosteroids; Muscle relaxation; Therapy

Abstract

V originále

We report the case of a patient suffering from duplicity of myotonic dystrophy type 1 and ulcerative colitis whose treatment for ulcerative colitis included repeated administrations of descending doses of methylprednisolone and in whom we found an association between methylprednisolone dosing and cessation of myotonia. Myotonia severity was expressed as relaxation time after voluntary contraction and as a patient-reported outcome using the Czech version of the Myotonia Behavior Scale. The patient was being treated for a flare of ulcerative colitis, starting with 32 mg of methylprednisolone and reducing the dose by 4 mg a week. The symptoms of myotonia began to wear off three weeks after starting methylprednisolone and had totally disappeared by four weeks after starting methylprednisolone. The first symptoms of myotonia returned about a month after the last dose of methylprednisolone and reached a peak of severity more than two months after the final dose. (C) 2020 Elsevier B.V. All rights reserved.

Links

MUNI/A/1325/2019, interní kód MU

Name: Diagnostika a patofyziologie neuropatické bolesti (Acronym: PNB)

Investor: Masaryk University, Category A

MUNI/A/1419/2018, interní kód MU

Name: Diagnostika a patofyziologie neuropatické bolesti (Acronym: PNB)

Investor: Masaryk University, Category A

Citovat

HORÁKOVÁ, Magda, Tomáš HORÁK, Josef BEDNAŘÍK and Stanislav VOHÁŇKA. The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1. Neuromuscular Disorders. London: Elsevier, 2020, vol. 30, No 5, p. 427-430. ISSN 0960-8966. Available from: https://dx.doi.org/10.1016/j.nmd.2020.03.004.

@article{1670257,
   author = {Horáková, Magda and Horák, Tomáš and Bednařík, Josef and Voháňka, Stanislav},
   article_location = {London},
   article_number = {5},
   doi = {http://dx.doi.org/10.1016/j.nmd.2020.03.004},
   keywords = {Myotonia; Myotonic dystrophy; Methylprednisolone; Corticosteroids; Muscle relaxation; Therapy},
   language = {eng},
   issn = {0960-8966},
   journal = {Neuromuscular Disorders},
   title = {The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1},
   url = {https://www.sciencedirect.com/science/article/pii/S0960896620300663?via%3Dihub},
   volume = {30},
   year = {2020}
}

TY  - JOUR
ID  - 1670257
AU  - Horáková, Magda - Horák, Tomáš - Bednařík, Josef - Voháňka, Stanislav
PY  - 2020
TI  - The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1
JF  - Neuromuscular Disorders
VL  - 30
IS  - 5
SP  - 427-430
EP  - 427-430
PB  - Elsevier
SN  - 09608966
KW  - Myotonia
KW  - Myotonic dystrophy
KW  - Methylprednisolone
KW  - Corticosteroids
KW  - Muscle relaxation
KW  - Therapy
UR  - https://www.sciencedirect.com/science/article/pii/S0960896620300663?via%3Dihub
L2  - https://www.sciencedirect.com/science/article/pii/S0960896620300663?via%3Dihub
N2  - We report the case of a patient suffering from duplicity of myotonic dystrophy type 1 and ulcerative colitis whose treatment for ulcerative colitis included repeated administrations of descending doses of methylprednisolone and in whom we found an association between methylprednisolone dosing and cessation of myotonia. Myotonia severity was expressed as relaxation time after voluntary contraction and as a patient-reported outcome using the Czech version of the Myotonia Behavior Scale. The patient was being treated for a flare of ulcerative colitis, starting with 32 mg of methylprednisolone and reducing the dose by 4 mg a week. The symptoms of myotonia began to wear off three weeks after starting methylprednisolone and had totally disappeared by four weeks after starting methylprednisolone. The first symptoms of myotonia returned about a month after the last dose of methylprednisolone and reached a peak of severity more than two months after the final dose. (C) 2020 Elsevier B.V. All rights reserved.
ER  -

HORÁKOVÁ, Magda, Tomáš HORÁK, Josef BEDNAŘÍK and Stanislav VOHÁŇKA. The Association of methylprednisolone dosing to cessation of myotonia in a patient with myotonic dystrophy type 1. \textit{Neuromuscular Disorders}. London: Elsevier, 2020, vol.~30, No~5, p.~427-430. ISSN~0960-8966. Available from: https://dx.doi.org/10.1016/j.nmd.2020.03.004.

Detailed Information on Publication Record